Alzchem Group Ag · XETR:ACT
Alzchem — Q2 2025 Earnings Presentation
30 slides from Alzchem's earnings presentation, Jul 30, 2025
Slide 1: Agile Science Pure Results
AGILE SCIENCE PURE RESULTS
Slide 2: Analyst Presentation, July 30, 2025
2 2025 ANDREAS NIEDERMAIER, CEO DR. GEORG WEICHSELBAUMER, CSO ANDREAS LOSLER, CFO July 30, 2025
Slide 3: Disclaimer
DISCLAIMER CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements about the business, financial condition and earnings performance of the Alzchem Group. These statements are based on assumptions and projections resting upon currently available info
Slide 4: Agenda — Analyst Presentation Q2 2025: Executive Summary
AGENDA — ANALYST PRESENTATION Q2 2025 Executive Summary
Slide 5: Highlights
HIGHLIGHTS us Strong development continues in 2025; all KPIs as expected H1 revenue slightly Specialty Chemicals above previous year; segment pushes figures: EBITDA with +9% revenue growth Nioousniaine omens significant growth; +18% EBITDA growth 9 P Construction activities for Nitroguanidine expans
Slide 6: Agenda — Business and financial details
AGENDA — ANALYST PRESENTATION Q2 2025 ll. Business and financial details
Slide 7: Basics & Intermediates
NITRALZ® Berlka’ G CaD BASICS & INTERMEDIATES The "Basics & Intermediates" segment comprises the production of basic and intermediate products that are marketed as independent products for example in agriculture. steel production and the automotive sector and as raw materials for the manufacture of
Slide 8: Basics & Intermediates Segment (in M€)
BASICS & INTERMEDIATES SEGMENT (in M€) Sales and EBITDA reductions on expected level SALES ANALYSIS A418 | 35.6 Volume fii a Q2. O38 Q4 Qt Q2 Q3 Q4 Qi Q2 2023 2023 2023 2024 2024 2024 2024 2025 2025 COMMENTS line of 14° 12 Q2. 03 Q4 QI Q2 3 4 QI QR 2023 2023 2023 2024 2024 2024 2024 2025 2025 1-6 1-
Slide 9: Specialty Chemicals
a eo ( CREAMINO Drmex' Bioselect®? DYHARD ##% Creapure* SPECIALTY CHEMICALS The "Specialty Chemicals" segment produces and sells high-quality growth products in the area of specialty chemicals.
Slide 10: Specialty Chemicals Segment (in M€)
SPECIALTY CHEMICALS SEGMENT (in Mé€) Segments growth trend continued t +16.7%y SALES ANALYSIS 100.1 85.8 Q2. Q3 Q4 QI Q2 O38 O4 QI Q2 2023 2023 2023 2024 2024 2024 2024 2025 2025 tributed * Human Nutrition — Higher volumes of Creapure® and Creavitalis® 27.9 Custom Manufacturing 22.8 nan and Euro} EB
Slide 11: Other & Holding
The "Other & Holding" segment offers infrastructure and energy supply services a at our locations for the chemicals segments and for external customers. a, . OTHER & HOLDING
Slide 12: Other & Holding Segment (in M€)
OTHER & HOLDING SEGMENT (in mé€) Regulated grid fees impact sales and result COMMENTS 8.5 | * Slight r chemical Regula * EBITDA ainly ting from reduced 2 8 84 A 2 3B 4 a @ eaehe 2023 2023 2023 2024 2024 2024 2024 2025 2025 0.1 Q2. 03 Q4- QI Q2 3 4 QI QR 1-6 1-6 2023 2023 2023 2024 2024 2024 2024 202
Slide 13: Financial Overview
FINANCIAL OVERVIEW Robust growth in EBITDA and earnings SALES (in M€) EBITDA (in M€) EBITDA margin (in %) Earnings per Share (in €) ghtly al hemical portion of Sp ment in net r +4.9% +7.7% +0.5 pp +10.8% group level mpen increased energy union its from 2024 well as EBITDA-margin Volume Price Currenc
Slide 14: Balance Sheet & Cashflow
Financial situation at positive net cash; increase in total assets BALANCE SHEET & CASHFLOW “ay 4 Ralance sheet KPls (TE 31.12.2024 30.06.2025 Deviation * Increase in balance sheet total resulting from increased CAPEX and Bal tte customer grants Inventories * Planned inventory increase ahead of carb
Slide 15: Outlook 2025 (in M€)
OUTLOOK 2025 (in me) The forecast remains valid — Growth in sales and EBITDA COMMENTS * Outlook for 2025 confirmed growth . - eneer to approx. * Major assumptions are still valid 580.0 ME growth to approx * Sales Growth FC 2025 FC 2025
Slide 16: Financial Calendar
FINANCIAL CALENDAR ANN Upcoming dates* (ay SEP 2 2025 Berenberg Stockholm Seminar SEP 3 2025 Commerzbank & ODDO BHF Corporate Conference SEP 9 2025 Berenberg Food Ingredients & Chemicals Conference SEP 23 2025 Baader Investment Conference SEP 24 2025 Berenberg and Goldman Sachs Conference SEP 30 202
Slide 17: Feedback
FEEDBACK We appreciate your feedback Were your expectations met? Are you missing any content? WE APPRECIATE YOUR FEEDBACK! QR-Code aera]
Slide 18: Investor Relations
alzchem group Investor Relations T +49 8621 86-2888 F +49 8621 86-502888 ir@alzchem.com
Slide 19: Agenda — Back-Up
AGENDA — ANALYST PRESENTATION Q2 2025 lll. Back-Up
Slide 20: Balance Sheet
© Alzchem Group AG / July 2025 BALANCE SHEET Alzchem Group ALZCHIEM GROUP (IN TE) 3112.2024 30.06.2025 Deviation Intangible assets 367 3,587 “BA -2.3% Tangible assets 192,976 217,682 24707 12.8% Investment properties Right of use (assets) 4023 3,323 100 “4% Investments accounted for using the equity
Slide 21: Pension Accounting (IFRS)
PENSION ACCOUNTING (IFRS) Alzchem Group (M€) IN FINANCIAL PENSION SERVICE NET INTEREST PENSION PENSION PENSION DEFERRED PENSION STATEMENT PROVISION costs costs PAYMENTS REMEASURE- PROVISION TAX ASSETS LIABILITY 31.12.2024 A MENTS 30.06.2025 30.06.2025 FINANCIAL RESULT oc BALANCE SHEET P&L CASHFLOW,
Slide 22: Income Statement
© Alzchem Group AG / July 2025 INCOME STATEMENT Alzchem Group ALZCHEM GROUP (NTE) core nomenon nen noms as aaas_—_—Deton G2) Revenue 150,064 136,191 128,937 139,040 144680 142,879 6688 5% Increase (+) / Decrease (-) in inventories of finished goods and work in progress -6521 12,682 -4310 7,169, 11,4
Slide 23: Income Statement
© Alzchem Group AG / July 2025 INCOME STATEMENT Alzchem Group aLzcHen GROUP (NTE) 2 | @ Deviation (969) sag yylRag ——_—Bevation vo Revenue 136,191 142,879 6,688 AM 286,255 287,559 1304 0.5% Increase (+)/ Decrease -Jninventeries of finshed goods and workinprogtess = 2662—=«34B 9200-72 a ee otter inco
Slide 24: Cashflow Statement
© Alzchem Group AG / July 2025 CASHFLOW STATEMENT Alzchem Group Q2 Q 1-6 CASHFLOW (IN ME) 2004 aap wa Concalidated earnings before taxes 19,088 22,003 42,247 Depraciation on fixed and intangible assets 6,453 6435 12,987 Decrease in pension provisions an 606 “1374 Lose (+) / Profit (-] from the sale
Slide 25: Segment Overview by Quarter
SEGMENT OVERVIEW BY QUARTER AX Alzchem Group v SALES YTD Q2 2025 caues a 2 8 4 OG 2 8 MW a @ a3 Deviation PY(O2) «PY Actusl_=—=—_‘evation PY (YON Te Te Te Te Te Te Te Te Te Te Te Te % Te Te Te % Basics & Intermediates 44,21 44,538 42,638 6,242 -15% 91147 78,244 “12,903 -14% Specialty Chemicals 69,54
Slide 26: Alzchem Group Locations
ALZCHEM GROUP LOCATIONS Production sites and sales companies COVENTRY (UK) ATLANTA (USA) $ g 3 & 5 z @ © SALES COMPANY
Slide 27: Vertically integrated production based on the NCN chain
© Alzchem Group AG / July 2025 Vertically integrated production of chemical products based on the NCN chain “VERBUND” — FULLY INTEGRATED BUSINESS MODEL us O O Segment Specialty Chemicals Segment Basics & Inter- mediates BENEFITS OF “VERBUND” * Full control of product quality and specifications * Low
Slide 28: Our Products and Markets
2025 3 Q 3 5 § a @ OUR PRODUCTS AND MARKETS AN Successful with proven and new products in various industries (ay MAIN PRODUCTS DESCRIPTION END-MARKETS CREAMINO® = Anutritional additive for poultry and pigs Feed additive Creapure’ — Creapure®, premium brand for creatine monohydrate as ingredient in s
Slide 29: Our Products and Markets
© Alzchem Group AG / July 2025 OUR PRODUCTS AND MARKETS Successful with proven and new products in various industries MAIN PRODUCTS DESCRIPTION END-MARKETS an Calcium carbide-based mixtures for hot metal desulphurization Steel industry Guanidine Salts Fuel for airbags. key production of the intermed
Slide 30: Key Share Data
© alzchem Group AG / July 2025 KEY SHARE DATA Share details as of July 28, 2025 SHARES OUTSTANDING. LAST CLOSING PRICE MARKET CAPITALIZATION TICKER WKN ISIN LISTING DESIGNATED SPONSOR 10,176,335 EUR 150.2 EUR 1,528.5 m ACT A2YNT3 DEOOOA2YNT30 Frankfurt Stock Exchange — Prime Standard Baader Bank AG